-
EP3843751
European procedure
Extract from the Register of European Patents
EP About this file: EP3843751
| EP3843751 - COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 23.02.2024 Database last updated on 24.08.2024 | |
| Former | Grant of patent is intended Status updated on 18.10.2023 | ||
| Former | Request for examination was made Status updated on 04.06.2021 | ||
| Former | The international publication has been made Status updated on 05.02.2021 | Most recent event Tooltip | 08.08.2024 | Lapse of the patent in a contracting state New state(s): SE | published on 11.09.2024 [2024/37] | Applicant(s) | For all designated states Ascentage Pharma (Suzhou) Co., Ltd. Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | For all designated states Ascentage Pharma Group Corp Limited 9/F, Wah Yuen Building 149 Queen's Road Central Hong Kong / HK | [2023/46] |
| Former [2021/27] | For all designated states Ascentage Pharma (Suzhou) Co., Ltd. Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | ||
| For all designated states Ascentage Pharma Group Corp Limited 9/F., Wah Yuen Building 149 Queen's Road Central Hong Kong / CN | Inventor(s) | 01 /
YANG, Dajun Unit 701, Building B7 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | 02 /
ZHAI, Yifan Unit 701, Building B7 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | 03 /
FANG, Douglas Dong Unit 701, Building B7 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | 04 /
TANG, Qiuqiong Unit 701, Building B7 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | [2021/27] | Representative(s) | Lavoix Bayerstraße 83 80335 München / DE | [2021/27] | Application number, filing date | 20847777.8 | 30.07.2020 | [2021/27] | WO2020CN105810 | Priority number, date | WO2019CN98625 | 31.07.2019 Original published format: PCT/CN2019/098625 | CN202010631089 | 03.07.2020 Original published format: CN202010631089 | [2021/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021018240 | Date: | 04.02.2021 | Language: | EN | [2021/05] | Type: | A1 Application with search report | No.: | EP3843751 | Date: | 07.07.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.02.2021 takes the place of the publication of the European patent application. | [2021/27] | Type: | B1 Patent specification | No.: | EP3843751 | Date: | 27.03.2024 | Language: | EN | [2024/13] | Search report(s) | International search report - published on: | CN | 04.02.2021 | (Supplementary) European search report - dispatched on: | EP | 14.04.2022 | Classification | IPC: | A61K31/496, A61K31/55, A61P35/00, A61P35/02, A61P35/04 | [2023/44] | CPC: |
A61P35/00 (EP,CN);
A61K45/06 (EP,CN,US);
A61K31/55 (EP,CN,US);
A61K31/496 (EP,CN,US);
A61K31/635 (CN,US);
A61K31/675 (CN,US);
| C-Set: |
A61K31/496, A61K2300/00 (CN,EP);
A61K31/55, A61K2300/00 (EP,CN);
A61K31/635, A61K2300/00 (CN);
A61K31/675, A61K2300/00 (CN) |
| Former IPC [2022/19] | A61K31/675, A61K31/496, A61K31/337, A61K31/282, A61K31/4745, A61K31/55, A61K31/635, A61P35/00, A61P35/02, A61P35/04, A61K45/06 | ||
| Former IPC [2021/27] | A61K31/675, A61K31/496, A61K31/337, A61K31/282, A61K31/4745, A61P35/00, A61P35/02, A61P35/04 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/27] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | KOMBINATIONSPRODUKT AUS BCL-2/BCL-XL-INHIBITOR UND CHEMOTHERAPEUTIKUM UND VERWENDUNG DAVON ZUR VORBEUGUNG UND/ODER BEHANDLUNG VON ERKRANKUNGEN | [2021/27] | English: | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | [2021/27] | French: | PRODUIT ASSOCIANT UN INHIBITEUR DE BCL-2/BCL-XL ET UN AGENT CHIMIOTHÉRAPEUTIQUE, ET UTILISATION ASSOCIÉE DANS LA PRÉVENTION ET/OU LE TRAITEMENT DE MALADIES | [2021/27] | Entry into regional phase | 31.03.2021 | National basic fee paid | 31.03.2021 | Search fee paid | 31.03.2021 | Designation fee(s) paid | 31.03.2021 | Examination fee paid | Examination procedure | 31.03.2021 | Examination requested [2021/27] | 25.10.2022 | Amendment by applicant (claims and/or description) | 19.10.2023 | Communication of intention to grant the patent | 15.02.2024 | Fee for grant paid | 15.02.2024 | Fee for publishing/printing paid | 15.02.2024 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 10.06.2022 | Renewal fee patent year 03 | 12.06.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | BG | 27.03.2024 | FI | 27.03.2024 | HR | 27.03.2024 | LT | 27.03.2024 | LV | 27.03.2024 | SE | 27.03.2024 | NO | 27.06.2024 | RS | 27.06.2024 | GR | 28.06.2024 | [2024/37] |
| Former [2024/36] | BG | 27.03.2024 | |
| FI | 27.03.2024 | ||
| HR | 27.03.2024 | ||
| LT | 27.03.2024 | ||
| LV | 27.03.2024 | ||
| NO | 27.06.2024 | ||
| RS | 27.06.2024 | ||
| GR | 28.06.2024 | ||
| Former [2024/35] | BG | 27.03.2024 | |
| FI | 27.03.2024 | ||
| HR | 27.03.2024 | ||
| LT | 27.03.2024 | ||
| NO | 27.06.2024 | ||
| RS | 27.06.2024 | ||
| GR | 28.06.2024 | ||
| Former [2024/33] | LT | 27.03.2024 | |
| NO | 27.06.2024 | Documents cited: | Search | [X] - KLANOVA MAGDALENA ET AL, "Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma", CLINICAL CANCER RESEARCH, US, vol. 22, no. 5, doi:10.1158/1078-0432.CCR-15-1191, ISSN 1078-0432, (20160301), pages 1138 - 1149, INTERNET, URL: https://watermark.silverchair.com/1138.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA_swggP3BgkqhkiG9w0BBwagggPoMIID5AIBADCCA90GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM681oV1tZGhcReAVyAgEQgIIDrhfBnZKT9C4nKBtHY0qroBYn1qzuJeDdrVUCOIUQF5WkucEmCtWbDpe0867e46PuyGgs5BzxhE6yFxdp9CLHCo029dvgTb5, (20220401), XP055908513 [X] 1,2,5-14 * abstract * * page 1144; figure 4 * * page 1140, column left, paragraph first * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-15-1191 |